TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B Stock

Certificat

DE000SN343N1

Delayed Deutsche Boerse AG 03:16:15 2024-05-20 EDT
1.27 EUR -0.78% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - H. LUNDBECK B
Current month-25.58%
1 month-31.91%
Date Price Change
24-05-20 1.27 -0.78%
24-05-17 1.28 -1.54%
24-05-16 1.3 +8.33%
24-05-15 1.2 -18.37%
24-05-14 1.47 -6.37%

Delayed Quote Deutsche Boerse AG

Last update May 20, 2024 at 03:16 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying H. LUNDBECK A/S
IssuerLogo Issuer Société Générale Société Générale
WKN SN343N
ISINDE000SN343N1
Date issued 2022-06-28
Strike 46.71 kr
Maturity Unlimited
Parity 1 : 1
Emission price 1.57
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.51
Lowest since issue 1.1
Spread 0.03
Spread %2.29%

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
-
More about the company

Ratings for H. Lundbeck A/S

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: H. Lundbeck A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.4 DKK
Average target price
39.96 DKK
Spread / Average Target
+6.84%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW